Nivolumab (Nivo) in Combination with Azacytidine (AZA) in Relapsed and Frontline Elderly Acute Myeloid Leukemia (AML)

Nivolumab, azacytidine, relapsed AML, frontline AML

Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Naval Daver, Guillermo Garcia-Manero, Sreyashi Basu, Jorge Cortes, Farhad Ravandi, Elias Jabbour, Rita Assi, Mark Brandt, Sherry Pierce, Tauna Gordon, Naveen Pemmaraju, Michael Andreeff, Jing Ning, Steven Kornblau, Tapan Kadia, Wilmer Flores, Jairo Matthe Tags: Checkpoint Inhibitors Source Type: research